Sales and Marketing

Showing 15 posts of 11524 posts found.

lars_nieba-web-image_0

Dr Lars Nieba appointed interim Chief Executive Officer at Nordic Nanovector

March 9, 2020 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Nordic Nanovector has appointed Dr Lars Nieba as the interim Chief Executive Officer. He is currently the company’s Chief Technology …
chris-thatcher-headshot_750xx1602-2136-155-0_1

Chris Thatcher to step down as President and CEO of Neuronetics

March 9, 2020 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Neuronetics, Inc and Chris Thatcher, the President and CEO, have mutually agreed that he will step down from his positions …
what-is-pharmacovigilance-328154

The need for evolution in pharmacovigilance

March 9, 2020 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing feature, pharma, pharmacovigilance

Pharmacovigilance is a critical function in ensuring public health, but is our current system built to tackle the challenges of …
palace-westminster-bridge-city

UK Government outlines emergency measures to tackle coronavirus

March 9, 2020 Sales and Marketing British Coronavirus, Chinese Coronavirus, Wuhan Coronavirus, coronavirus

The British Government has outlined its emergency legislation to tackle coronavirus in which people could leave work to become volunteers …

FDA authorises first therapy to tackle cortisol overproduction in Cushing’s disease

March 9, 2020 Sales and Marketing Cushing's disease, FDA, pharma

The FDA has moved to approve its first therapy to directly treat the overproduction of the hormone cortisol which is …

Coronavirus forcing Eli Lilly employees to work from home

March 9, 2020 Sales and Marketing Chinese Coroanvirus, Eli Lilly, Eli Lilly Coronavirus, Wuhan Coronavirus, coronavirus

Eli Lilly is asking some of its employees to work from home to stop the spread of coronavirus on its …
20181130-niaid-hiv-test

Uganda finalising clinical trials on new injectable HIV drug

March 9, 2020 Sales and Marketing AIDS, HIV, Uganda HIV, Uganda HIV/AIDS, uganda

Uganda is preparing to enter the final stages of developing a new HIV treatment to reduce stigma and discrimination of …
nice_new_london_office_internal_3_web

NICE shoots down Dupixent for severe asthma

March 9, 2020 Sales and Marketing Dupixent, NHS, NICE, Regeneron, Sanofi, UK, asthma

NICE, the NHS’ drug watchdog in England and Wales, has announced its decision not to recommend Sanofi and Regeneron’s IL-4 …
shutterstock_138095450

New study calculates median drug development costs at circa $1 billion

March 5, 2020 Manufacturing and Production, Research and Development, Sales and Marketing drug development, drug prices, pharma

New research has pinned a concrete figure on the perennial industry question: how much does it cost to bring a …

China approves Roche’s Actemra to fight severe complications stemming from coronavirus

March 5, 2020 Sales and Marketing Actemra, China, Roche, coronavirus, pharma

China has moved to authorise Roche’s Actemra (tocilizumab) as a treatment for severe complications from contracting the COVID-19 coronavirus in …
gilead_hq_at_stockley_park_london_2

Gilead acquires immuno-oncology firm Forty Seven in $4.9 billion deal

March 3, 2020 Manufacturing and Production, Sales and Marketing Cancer, Forty Seven, Gilead, acquisition, oncology, pharma

Gilead has revealed it is to acquire the immunology firm Forty Seven in a deal valued at $95.50 per share …

Sanofi scores FDA approval for Sarclisa combo in relapsed, refractory multiple myeloma

March 3, 2020 Manufacturing and Production, Sales and Marketing Cancer, Sanofi, Sarclisa, multiple myeloma, pharma

Sanofi’s monoclonal antibody and CD-38 inhibitor Sarclisa (isatuximab-irfc) has been awarded marketing authorisation from the FDA in the treatment of …
michael-jewell

Funding overview for the pharmaceutical industry and outlook for 2020

March 2, 2020 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2020, M&A, MA, feature, mergers & acquisitions, opinion, pharma

This article was originally published in the January/February 2020 issue of Pharmafocus.With the advent of a New Year, Michael Jewell, …
gwpharma

GW Pharma takes back control of UK Sativex sales from Bayer

March 2, 2020 Sales and Marketing Bayer, GW Pharma, Sativex, UK

British firm GW Pharmaceuticals has revealed that it plans to reclaim the commercialisation rights to market its cannabis-based multiple sclerosis …
The Gateway to Local Adoption Series

Latest content